Alessandro Rizzo1, Veronica Mollica2, Matteo Santoni3, Francesco Massari2,4. 1. Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari, 70124, Italy. 2. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, 40138, Italy. 3. Oncology Unit, Macerata Hospital, Macerata, Italy. 4. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, 40138, Italy.
Abstract
Aims: We performed a meta-analysis to investigate the predictive value of PD-L1 in metastatic renal cell carcinoma (mRCC) patients receiving immune-based combinations versus sunitinib monotherapy. Materials & Methods: Outcomes of interest included OS and PFS; HRs and their 95% CIs were extracted. Results: The pooled HR for OS was 0.71 (95% CI: 0.61-0.84) and 0.75 (95% CI: 0.68-0.82) in PD-L1-positive and unselected patients, respectively. Similarly, HR for PFS was 0.68 (95% CI: 0.54-0.85) in PD-L1-positive patients and 0.63 (95% CI: 0.50-0.78) in the ITT population, respectively. Conclusion: Slight differences were observed between PD-L1-positive patients and the ITT population, and these findings support the limited role of PD-L1 as predictive biomarkers in this setting.
Aims: We performed a meta-analysis to investigate the predictive value of PD-L1 in metastatic renal cell carcinoma (mRCC) patients receiving immune-based combinations versus sunitinib monotherapy. Materials & Methods: Outcomes of interest included OS and PFS; HRs and their 95% CIs were extracted. Results: The pooled HR for OS was 0.71 (95% CI: 0.61-0.84) and 0.75 (95% CI: 0.68-0.82) in PD-L1-positive and unselected patients, respectively. Similarly, HR for PFS was 0.68 (95% CI: 0.54-0.85) in PD-L1-positive patients and 0.63 (95% CI: 0.50-0.78) in the ITT population, respectively. Conclusion: Slight differences were observed between PD-L1-positive patients and the ITT population, and these findings support the limited role of PD-L1 as predictive biomarkers in this setting.
Authors: Sara Elena Rebuzzi; Alessio Signori; Marco Stellato; Daniele Santini; Marco Maruzzo; Ugo De Giorgi; Paolo Pedrazzoli; Luca Galli; Paolo Andrea Zucali; Emanuela Fantinel; Claudia Carella; Giuseppe Procopio; Michele Milella; Francesco Boccardo; Lucia Fratino; Roberto Sabbatini; Riccardo Ricotta; Stefano Panni; Francesco Massari; Mariella Sorarù; Matteo Santoni; Alessio Cortellini; Veronica Prati; Hector Josè Soto Parra; Francesco Atzori; Marilena Di Napoli; Orazio Caffo; Marco Messina; Franco Morelli; Giuseppe Prati; Franco Nolè; Francesca Vignani; Alessia Cavo; Giandomenico Roviello; Miguel Angel Llaja Obispo; Camillo Porta; Sebastiano Buti; Giuseppe Fornarini; Giuseppe Luigi Banna Journal: Front Oncol Date: 2022-09-23 Impact factor: 5.738